TABLE 3.

Prescription characteristics are shown for all weight‐negative medications, with each category further broken down into percentage (n) of total sample of prescriptions in each class as well as median (and range) of doses, duration of medication prescriptions, and interval follow‐up of MELD and weight in days

Weight‐loss medication	% (n)	Total dose median [range]	Median time on treatment (days) [range]	Median time to MELD follow‐Up (days) [range]	Median time to weight follow‐Up (days) [range]
Metformin	63% (24)	1000 [500–2000] (mg/day)	1153 [172–2462]	363 [47–622]	335 [140–463]
GLP‐1 agonists	39% (15)	‐	708 [36–1586]	353 [47–794]	296.5 [64–439]
Liraglutide	‐	1.2 [1.2–2.4] (mg/day)	616.5 [36–1586]	353 [91–794]	305 [64–366]
Dulaglutide	‐	0.75 [0.25–1.5] (mg/week)	567 [198–929]	327 [47–546]	140 [113–364]
Exenatide	‐	15 [10–20] (mcg/day) a	875 [249–1166]	332.5 [228–441]	332 [228–439]
SGLT‐2 inhibitors	24% (9)	‐	357 [12–1314]	363 [47–454]	326 [94–737]
Canagliflozin	‐	300 [100–300] (mg/day)	357 [95–1314]	395 [94–454]	326 [94–737]
Dapagliflozin	‐	5 (mg/day)	12	b	c
Empagliflozin	‐	10 [10–25] (mg/day)	519 [13–708]	47	252 [140–364]
Bupropion	16% (6)	225 [100–300] (mg/day)	926.5 [346–3509]	256 [244–349]	356.5 [258–618]
Topiramate	8% (3)	50 [25–75] (mg/day)	1011 [750–1011]	431 [391–589]	397 [376–500]
Phentermine	8% (3)	16 [15–30] (mg/day)	135 [29–146]	215 [213–217]	135 [29–151]
Naltrexone	5% (2)	27 [4–50] (mg/day)	734.5 [102–1367]	455 [101–809]	232.5 [101–364]
Lorcaserin	3% (1)	20 (mg/day)	275	317	330

Abbreviation: MELD, Model for End‐Stage Liver Disease.

^a A 2 mg/week dose was considered equivalent to 10 mcg/day.

^b No MELD labs meeting data collection criteria.

^c Excluded from weight loss analysis due to prescription period <30 days.